HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.

Abstract
This study concerns the history of a male patient with hormone-producing adrenal cortical carcinoma. Six months after resection of the primary tumor, lymph node metastases were detected and treatment with o,p'-DDD [1,1 dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane] (Lysodren/mitotane) was started. After 2 years, a complete histologically proven response was confirmed at laparotomy and is still sustained 2 years after the discontinuation of treatment. As a consequence of insufficient steroid replacement the patient suffered bouts of adrenal insufficiency. After 1 year of treatment, the measurement of the plasma levels of o,p'-DDD showed an accumulation of the drug. At that time, progressive major central nervous system toxicity occurred, which proved to be reversible on discontinuation of the treatment.
AuthorsE Boven, J B Vermorken, H van Slooten, H M Pinedo
JournalCancer (Cancer) Vol. 53 Issue 1 Pg. 26-9 (Jan 01 1984) ISSN: 0008-543X [Print] United States
PMID6360329 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Mitotane
Topics
  • Adrenal Cortex (drug effects)
  • Adrenal Gland Neoplasms (drug therapy, surgery)
  • Carcinoma (drug therapy, surgery)
  • Humans
  • Laparotomy
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Mitotane (blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: